R289 continues to be generally well tolerated and at doses of ≥500 mg QD preliminary efficacy was observed in elderly, heavily pre-treated lower-risk MDS patients RBC-TI was achieved by 33% (6/18) of ...

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The ...

Despite being in the age of tech-stock blue-sky investing, many investors still adopt a more traditional strategy; buying shares in profitable companies like Rigel Pharmaceuticals (NASDAQ:RIGL). Now ...

Shares of Rigel Pharmaceuticals RIGL have rallied 76.7% in the past three months. This stock price rally can be attributed to growing investor confidence regarding the strong growth of the company’s ...

Four months ago, Rigel Pharmaceuticals spent just $2 million—plus ponying up another $233 million in potential milestones—to acquire Forma Therapeutics’ leukemia drug Rezlidhia. On Thursday, Rigel got ...

Rigel Technologies Inc. (the "Company") is pleased to announce it has entered into a non-binding letter of intent (the "LOI"), dated December 15, 2025, to acquire all of the issued and outstanding ...

Rigel Pharmaceuticals RIGL is scheduled to report third-quarter 2025 results on Nov. 4, after market close. The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $61.6 ...

Rigel Pharmaceuticals' strategic acquisitions of GAVRETO and REZLIDHIA, along with strong TAVALISSE sales, position the company for significant growth and potential profitability. Despite historical ...

Rigel’s IRAK1/4 inhibitor, R289, has shown promising results in a Phase 1b trial for relapsed/refractory lower-risk myelodysplastic syndrome (LR-MDS). The initial data presented at ASH 2024 ...

A small but meaningful change is coming to the AAD Election: a shorter timeline. This change, recommended by the Ad Hoc Task ...